Sort
48,018 grants matching “immunotherapy”
NOVEL VACCINE TARGETS FOR EARLY STAGE BREAST CANCER
$401,066Benaroya Research Inst At Virginia Mason · R01 · FY2002 · CA
Developmental Funds
$401,062C Kent Osborne · Baylor College Of Medicine · P30 · FY2021 · CA
Engineering of pan-neutralizing anti-HIV envelope antibodies
$401,045Mohammad Mohseni Sajadi · University Of Maryland Baltimore · R01 · FY2023 · AI
Biomaterial Cancer Vaccines that Generate Patient-Specific Antigen In Situ
$400,995David J Mooney · Harvard University · R01 · FY2019 · CA
Collaborative Innate-Adaptive Immune Regulation of Tumor Progression
$400,975Matthew F Krummel · University Of California, San Francisco · U01 · FY2009 · CA
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations
$400,975Eric Collisson · University Of California, San Francisco · R01 · FY2022 · CA
Functional Immunomics Core
$400,973Bing Li · University Of Louisville · P20 · FY2024 · GM
Brain Tumor Immunotherapy
$400,968Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy
$400,950John H Sampson · Duke University · R01 · FY2022 · CA
Mechanisms by which effector T cells modulate endogenous remyelination
$400,950Peter A Calabresi · Johns Hopkins University · R37 · FY2014 · NS
High-Parameter Cytometry Shared Resource
$400,938Christine Beeton · Baylor College Of Medicine · P30 · FY2020 · CA
Defining Pathologic Immune Dysregulation in 2019-CoV: Opportunities for Risk Stratification and Therapeutic Immune Modulation
$400,938C Kent Osborne · Baylor College Of Medicine · P30 · FY2020 · CA
Vanderbilt Network Lead Academic Participating Site for the NCTN
$400,925Jordan D Berlin · Vanderbilt University Medical Center · UG1 · FY2021 · CA
Joint receptor and protein expression immunophenotyping through split-pool barcoding
$400,906Georg Seelig · University Of Washington · R33 · FY2022 · CA
Microbiome-Mediated Tumor Immunomodulation in a Pathomimetic Colorectal Cancer Chip
$400,890Hyun Jung Kim · Cleveland Clinic Lerner Com-Cwru · R33 · FY2025 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$400,890Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$400,890Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer
$400,890Hui-Kuan Lin · Duke University · R01 · FY2023 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$400,868Fumito Ito · University Of Southern California · R01 · FY2023 · CA
Research Training In Hematology
$400,864John Patrick Sheehan · University Of Wisconsin-Madison · T32 · FY2015 · HL
Developmental Funds
$400,844Edward Chu · Albert Einstein College Of Medicine · P30 · FY2024 · CA
Clinical Neuroimmunology of Vaccines in Brain Tumors
$400,801John H Sampson · Duke University · R01 · FY2021 · NS
NRG Oncology Annual BIQSFP Progress Reports
$400,777Norman Wolmark · Nrg Oncology Foundation, Inc. · U10 · FY2025 · CA
Engineering HIV-specific T cells that have improved function and persistence
$400,756E. John Wherry · University Of Pennsylvania · U19 · FY2023 · AI
CAREER: An Advanced 3D Tissue Model for the Detection and Study of an Allergic Inflammatory Response
$400,738Heather Fahlenkamp · Oklahoma State University · · FY2012 · ENG